PharmaVentures has announced its agreement with Growthink Research, the US-based market research company, to distribute the Growthink Research Venture Capital database to PharmaVentures' customers worldwide. (PRWeb May 21, 2008) Read the full story at http://ww1.prweb.com/releases/2008/05/prweb955604.htm
Pro-Pharmaceuticals has signed a collaboration agreement with BioCancell Therapeutics, to target destruction of H19 genes in cancer cells by delivering small interfering Ribonucleic Acid through intravenous administration of Pro-Pharmaceuticals's Davanat and BioCancell's BC-819 patient-oriented, targeted therapy.
PerkinElmer has announced that Michael Battles, the company's vice president and controller, will lead the finance function on an interim basis, reporting directly to president and CEO, Robert Friel.
Aureon Laboratories has introduced new Prostate Px+, the first commercial test said to predict prostate cancer progression and disease recurrence at the time of diagnosis.
VGX Pharmaceuticals has submitted two separate investigational new drug applications to the FDA for Phase I clinical studies of VGX-3100 and VGX-3400 vaccines. Both the candidate vaccines have been developed using VGX's integrated DNA vaccines and therapies platform and are
Bayer HealthCare Pharmaceuticals has announced that a reformulation of the liquid Leukine 500mcg vial has received the FDA's approval and is now available for patients and physicians in the US.
Amgen has announced positive findings from a head-to-head, double-blind trial comparing the effects of denosumab in post-menopausal women with low bone mass transitioned from weekly alendronate versus continued alendronate therapy on bone mineral density.
Neose Technologies has received a milestone payment from Novo Nordisk, under a license agreement for the use of its GlycoPEGylation technology to develop a next-generation version of Factor IX.
Given Imaging has announced the results of an eight-center European study, which confirmed that PillCam Colon demonstrates encouraging results for detecting colo-rectal polyps compared to colonoscopy.
Intellect Neurosciences has entered into a license agreement with Wyeth and Elan Pharma International regarding certain of Intellect's patents and patent applications related to antibodies and methods of treatment for Alzheimer's disease.
Gloucester Pharmaceuticals has reported positive results from a Phase IIb registration trial of romidepsin in patients with advanced cutaneous T-cell lymphoma.
OmniComm Systems has entered into a five-year, multi-million dollar electronic data capture enterprise agreement with a major west coast biotechnology company.
